## SERIAL NO. ATTY. DOCKET NO. INFORMATION DISCLOSURE 39042-0036 10/579,088 **STATEMENT** APPLICANT: Manzer Durrani PTO-1449 FILING DATE: 11/11/2004 GROUP: U.S. PATENT DOCUMENTS **CLASS SUBCLASS** FILING DATE DATE **NAME EXAMINER'S** PATENT NO. **INITIALS** 04-17-79 Pecina 4,150,071 4,198,969 04-22-80 Virag. 4,253,468 03-03-81 Lehmbeck 11-24-81 Craighero 4,301,970 06-12-84 Hughes 4,453,542 Kawasaki 07-08-86 4,599,311 4,620,670 11-04-86 Hughes 03-22-88 Barr, et al. 4,732,973 06-05-90 Kawasaki, et al. 4,931,373 5,093,316 03-03-1992 Lezdey, et al. 07-28-92 Lezdey, et al. 5,134,119 5,150,071 09-22-92 Bouzidi 5,166,134 Lezdey, et al. 11-24-92 06-08-93 Kawasaki, et al. 5,218,091 04-08-97 Roosdorp, et al. 5,618,786 12-08-87 Insley, et al. 4,711,848 07-14-98 Lezdey, et al. 5,780,440 5,993,783 11-30-99 Eljamal, et al. Niven, et al. 2001/006939 07-05-01 FOREIGN PATENT DOCUMENTS TRANSLATION **CLASS SUBCLASS EXAMINER'S** PATENT NO. DATE COUNTRY **INITIALS** YES NO 11-02-88 EP $\Box$ EP 0289 336 A DATE CONSIDERED **EXAMINER**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		SHEET 2 OF 3
INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39042-0036	SERIAL NO. 10/579,088
	APPLICANT: Manzer Durrani	
F10-1449	FILING DATE: 11/11/2004	GROUP:
OTHER DOCUMENTS	(Including Author, Title, Date, Pertir	ent Pages, Etc.)
Carlson, et al., J. Clin. Invest	., Vol. 83, pp. 1183-1190, 1989	
Carrell, et al., Nature, Vol. 29	98, pp. 329-334, 1982	
Carter, et al., Nucleic Acids I	Research, Vol. 13, No. 12, pp. 4431-444	3, 1985
	re of Protein Pharmaceuticals, Edited by y, Vol. 14, Kluwer Academic/Plenum I	
Dycaico, et al., Science, Vol.	242, No. 4884, pp. 1409-1412, 1988	
Gadek, et al., The Metabolic York, pp. 1450-1467, 1982	Basis of Inherited Diesease (Stanbury, J	J.B. et al., Eds.) McGraw-Hill, New
GenBank Accession No. AA	B59375	
Handbook of Pharmaceuetica Information Resources, Inc. p	al Additives 2 <sup>nd</sup> Edition, Complied by Mop. 797-798, 2002	lichael and Irene Ash, Synapse
Hunnighake, et al., Am. Rev.	Respir. Dis., Vol. 128, pp. 833-838 198	33
Lomas, et al., Nature, Vol. 35	57, pp. 605-607, 1992	
Neddleman & Wunsch, J. Mo	ol. Biol., Vol. 48, p. 443-453, 1970	
Pearson & Lipman, Proc. Na	t'l. Acad. Sci. USA, Vol. 85, p. 2444-24	48, 1988
Design of Stable Protein Form	ein Formulation Development, Byeong mulations: Theory and Practice, Eidted otechnology Vol. 13, Kluwer Academic	by John F. Carpenter and Mark C.
XAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.

		SHEET J OF J
INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
	39042-0036	10/579,088
	APPLICANT: Manzer Durrani	
	FILING DATE: 11/11/2004	GROUP:
OTHER DOCUMENTS (	Including Author, Title, Date, Pertino	ent Pages, Etc.)
Smith & Waterman, Adv. Appl. Math., Vol. 2, p. 482, 1981		
Smith, et al., J. Clin. Invest., V	ol. 84, pp. 1145-1154, 1989	
Protein Formulations: Theory	s, Theodore W. Randolph, LaToya S. Jo and Practice, Edited by John F. Carpert y, Vol. 13, Kluwer Academic/Plenum Pr	er and Mark C. Manning,
Wells, et al., Gene, Vol. 34, p.	315-323, 1985	
Wells, et al., Philos Trans. R. Soc. London SerA, Vol. 317, p. 415-423, 1986		
Wu, et al., Proc. Natl. Acad. S	ci., Vol. 91, pp. 9014-9018, 1994	
Zoller, et al., Nucleic Acids Re	esearch, Vol. 10, No. 20, p. 6487, 1982	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.